These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10351157)

  • 21. Blood supplies hit by vCJD fear.
    Strachan-Bennett S
    Nurs Times; 2004 Jan 6-12; 100(1):6. PubMed ID: 14735624
    [No Abstract]   [Full Text] [Related]  

  • 22. Leukocyte reduction of blood components: public policy and new technology.
    Dzik S; Aubuchon J; Jeffries L; Kleinman S; Manno C; Murphy MF; Popovsky MA; Sayers M; Silberstein LE; Slichter SJ; Vamvakas EC
    Transfus Med Rev; 2000 Jan; 14(1):34-52. PubMed ID: 10669939
    [No Abstract]   [Full Text] [Related]  

  • 23. Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force.
    Transfus Med; 1998 Mar; 8(1):59-71. PubMed ID: 9569462
    [No Abstract]   [Full Text] [Related]  

  • 24. Leukoreduction of blood components.
    Dzik WH
    Curr Opin Hematol; 2002 Nov; 9(6):521-6. PubMed ID: 12394176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The quality of blood starts with its collection.
    Loos JA
    Vox Sang; 1994; 67 Suppl 3():77-9. PubMed ID: 7975516
    [No Abstract]   [Full Text] [Related]  

  • 26. Scarce resources in an affluent society. Striving for zero risk?
    Gorham M
    Vox Sang; 2002 Aug; 83 Suppl 1():133-6. PubMed ID: 12617122
    [No Abstract]   [Full Text] [Related]  

  • 27. Leukocyte-poor platelet concentrates in routine production: preparation and cost.
    Olthuis H; Verhagen C; Valk L; Laport R
    Transfus Sci; 1998 Dec; 19(4):385-7. PubMed ID: 10351164
    [No Abstract]   [Full Text] [Related]  

  • 28. Current and emerging infectious risks of blood transfusions.
    Busch MP; Kleinman SH; Nemo GJ
    JAMA; 2003 Feb; 289(8):959-62. PubMed ID: 12597733
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapy with cellular blood components].
    Eichler H; Klüter H
    Internist (Berl); 2001 May; 42(5):760-8. PubMed ID: 11400584
    [No Abstract]   [Full Text] [Related]  

  • 30. Selective or universal leucodepletion: the Italian experience.
    Accorsi P; Iacone A
    Transfus Sci; 2000; 22(1-2):65-7. PubMed ID: 10771386
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical aspects of platelet transfusion.
    Williamson LM
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):643-6. PubMed ID: 1333290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Universal leukodepletion of blood and febrile transfusion reactions.
    Rennie I; Rawlinson PS; Clark P
    Transfus Med; 2001 Apr; 11(2):115. PubMed ID: 11299029
    [No Abstract]   [Full Text] [Related]  

  • 33. National French observatory of the quality of blood components for transfusion.
    Chabanel A; Masse M; Begue S;
    Transfus Clin Biol; 2008 Jun; 15(3):85-90. PubMed ID: 18524661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.
    Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J
    Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multilayer-strategy to enhance optimal safety of the blood supply: The role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: Moderator views.
    Seghatchian J
    Transfus Apher Sci; 2015 Apr; 52(2):233-6. PubMed ID: 25748230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Under pressure.
    Siddall R
    Health Serv J; 2003 Aug; 113(5869):12-3. PubMed ID: 12953390
    [No Abstract]   [Full Text] [Related]  

  • 37. Variant Creutzfeldt-Jakob disease and prions in the blood supply.
    Rohwer RG; Drohan W
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166
    [No Abstract]   [Full Text] [Related]  

  • 38. Quality control of leucoreduced cellular blood components in France.
    Chabanel A; Andreu G; Carrat F; Hervé P
    Vox Sang; 2002 Feb; 82(2):67-71. PubMed ID: 11906669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Japan plans blood-donor restrictions to combat vCJD.
    Fuyuno I
    Nature; 2005 Mar; 434(7031):260. PubMed ID: 15772611
    [No Abstract]   [Full Text] [Related]  

  • 40. Universal leucodepletion to reduce potential risk of transmission of new-variant Creutzfeld-Jakob disease.
    Turner M
    Br J Haematol; 2000 Sep; 110(3):745-8. PubMed ID: 10997991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.